Environmental Illness

Research Outcomes Include a Novel IgG4 Monoclonal Antibody-based Therapeutic Approach for Addressing Peanut Allergy SOUTH SAN FRANCISCO, Calif., Feb. 22, 2024 /PRNewswire/ -- IgGenix, Inc., a preclinical antibody discovery and development company taking a revolutionary approach to address IgE-mediated diseases, today announced the continued advancement of IGNX001, an IgG4 monoclonal antibody-based therapeutic candidate for peanut allergy. The company also announced data demonstrating how IgGenix's novel antibodies can be used as effective reagents in allergen quantification and testing. These data will be presented during the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting, taking place in Washington, D.C., on February 23-26, 2024, in a poster presentation and oral presentation respectively. Highlights from AAAAI: IGNX001 is a promising candidate for competitively inhibiting the allergic cascade by directly binding peanut allergen, thereby preventing IgE-mediated effector cell activation. IGNX001 prevented severe anaphylactic response to peanut challenge in a mouse model of peanut allergy. IgGenix's novel antibodies can replace antiquated approaches to quantifying allergen content in commercial allergen extracts. "Peanut allergy continues to be a significant unmet medical need among both adults and children as there are currently no therapeutic options with a fast onset of action and highly favorable safety profile. There remains a clear need to provide a safe, fast-acting, and effective allergen-specific treatment option that improves quality of life and protects against the allergic response resulting from accidental exposure. We are very pleased at the continued positive preclinical data supporting our peanut allergy candidate IGXN001 as we prepare to enter the clinic later this year," said Jessica Grossman, MD, Chief Executive Officer of IgGenix. "Through our proprietary SEQ SIFTER™ antibody discovery platform, IgGenix has created a significant foundation for developing high-affinity IgG4 antibodies that provide a potential path to a new standard of care for preventing severe allergic reactions." Poster Presentation Title: IGNX001 Abrogates Peanut-mediated Mast Cell Degranulation and Murine Anaphylaxis Authors: Croote D., Wong J. J.W., Creeks P., Aruva V., Grossman J., Ferrini, R., Lowman H.B., Landers J.J., O'Konek J.J., Thomas R. Presenter: Derek Croote, PhD, IgGenix Oral Presentation: Title: Cat Pelt/Hair Extract US Potency: Updating the Predicate Fel d 1 RID with a mAb-based ELISA Authors: Hamilton R.G., Croote D., Chen A., Dobrovolskaia K., Grossman J., Rabin R.L. Presenter: Robert G. Hamilton, PhD, MS, Director, Dermatology, Allergy and Clinical Immunology (DACI) Reference Laboratory, Johns Hopkins University School of Medicine The abstracts can be accessed here. About IgGenix IgGenix is a privately held antibody discovery and development company taking a revolutionary approach to directly address allergies and atopic diseases. Through our proprietary SEQ SIFTER™ discovery platform, developed from foundational research of co-founders Stephen Quake, Kari Nadeau, and Derek Croote of Stanford University, we isolate and re-engineer fully human, high-affinity, allergen-specific antibodies designed to block and prevent the allergic cascade. By targeting common immunodominant allergens and their most important epitopes across the patient population, we intend to treat allergic pediatric and adult patients alike across food and environmental allergies. This novel approach may prevent life-threatening allergic reactions, saving lives and reducing the constant fear that affects millions of people living with severe allergies. SOURCE IgGenix

Madison Taylor Indoor Environmental expertly tackles mold problems in D.C., Maryland, and Virginia, helping residents and businesses improve their indoor air quality. MCLEAN, Va., Dec. 12, 2023 /PRNewswire/ -- In a groundbreaking move, Madison Taylor Indoor Environmental is proud to announce a new initiative aimed at providing support for clients suffering from mold-related illnesses. This compassionate program offers free phone consultations with certified indoor environmentalists to help determine the most effective course of action, whether it involves detailed inspection and testing, a remediation plan or simply expert advice. A Commitment to Health and Well-Being Recognizing the critical link between environmental factors and health, Madison Taylor Indoor Environmental has stepped up to offer guidance and support. With over 24 years of experience in addressing the sources in homes and buildings creating conditions conducive to health issues caused by microbial contamination, the company's expertise is now more accessible than ever. Expert Help at Your Fingertips This initiative allows individuals experiencing health concerns potentially linked to mold exposure to receive immediate professional input. Our certified indoor environmentalists are on hand to provide insights into possible mold issues and advise on next steps, ensuring that every query is met with knowledge and empathy. Services Tailored to Your Needs In addition to this new consultation service, Madison Taylor Indoor Environmental continues to offer a comprehensive suite of indoor air quality solutions: Mold Testing and Remediation: Expert identification and elimination of mold. VOCs Testing: Identification and management of volatile organic compounds. Bacteria, Asbestos, and Lead Testing: Specialized testing for a variety of environmental hazards. Comprehensive Air Quality Assessments: Full evaluations of indoor air contaminants. Two Decades of Trust and Excellence Since its inception in 2000, Madison Taylor Indoor Environmental has been a beacon of trust and excellence in the indoor environmental industry, serving close to 60,000 clients. This new initiative is a testament to our ongoing commitment to indoor air quality health and safety throughout the community. Get the Support You Deserve If you're concerned about the source of your mold-related health issues, don't hesitate to take advantage of this free consultation. Contact Madison Taylor Indoor Environmental at ( 877) 932-4652 for expert advice and peace of mind. Contact Information: John Taylor (CIE) at Madison Taylor Indoor Environmental Phone: 877-932-4652 Email: [email protected] Website: Madison Taylor Indoor Environmental - Your Health, Our Mission. About Madison Taylor Indoor Environmental: Madison Taylor Indoor Environmental is a company with over 20 years of experience in mold inspection and remediation. They provide services related to identifying and removing mold in indoor environments to improve indoor air quality and prevent healthy issues. With their extensive experience in the field, they are a trusted provider of mold-related services. SOURCE Madison Taylor Indoor Environmental

– Fast Track Designation accelerates ADP101's development path for the treatment of mono- and multi-food allergy – – Phase 1/2 Harmony data for ADP101 recently presented at the 2023 American College of Asthma, Allergy and Immunology (ACAAI) Meeting demonstrate dose-dependent, clinically meaningful desensitization responses and a favorable safety profile in pediatric patients allergic to qualifying foods – Alladapt Immunotherapeutics, Inc., a private, clinical-stage biopharmaceutical company developing prescription therapeutics to address IgE-mediated food allergy, today announced that ADP101, its investigational multi-food oral immunotherapy (mOIT) designed to simultaneously treat allergy to one or more of the world’s most significant food allergens, received Fast Track Designation from the U.S. Food and Drug Administration (FDA). ADP101 is the most advanced multi-food OIT pharmaceutical candidate in development. Ashley Dombkowski, Ph.D., Chief Executive Officer and Co-Founder of Alladapt, said, “The FDA’s decision to grant ADP101 Fast Track Designation signifies an important milestone for people suffering from the substantial burden of food allergy, which requires constant, meticulous avoidance of all consumption or contact with allergens. Our team is thrilled to be at the forefront of developing a new treatment that addresses such a huge unmet need. We are excited to collaborate even more closely with the FDA as we move ahead to expedite development of this important therapy.” There are currently no FDA-approved OIT treatments for multi-food allergy or for allergy to foods other than peanut. In an independent study of patients who sought treatment for food allergic reactions in the emergency department over a 12-month period, 93% were either multi-allergic or allergic to foods other than peanut, with only 6.6% allergic to peanut alone.1 This amplifies the need for interventions that can target a breadth and depth of allergens. The Fast Track Designation grant letter provides FDA endorsement for expedited development of ADP101 as a treatment for food allergy, including the simultaneous treatment of multiple food allergies and the treatment of single food allergies, in children (4-17 years of age) with confirmed allergy to one or more of the following 15 foods contained in the drug product: almond, cashew, chicken egg, codfish, cow milk, hazelnut, peanut, pecan, pistachio, salmon, sesame seed, shrimp, soy, walnut and wheat. FDA’s Fast Track program is designed to expedite the development of new drugs intended to treat serious or life-threatening conditions. Fast Track allows more frequent meetings and written communications with FDA to discuss the drug's development plan, clinical trial design, and data collection. Fast Track designated drugs can take advantage of Rolling Review, wherein a company can submit completed sections of its Biologic License Application (BLA) for review by FDA, rather than waiting until every section of the BLA is completed before the entire application can be reviewed. Such drugs are also eligible for Priority Review, if relevant criteria are met. This designation aims to bring important new drugs to patients earlier and address unmet medical needs.2 The Fast Track designation for ADP101 was supported by results from Alladapt's Phase 1/2 Harmony trial (NCT04856865) evaluating the efficacy and safety of ADP101 for inducing desensitization in patients with single or multiple food allergies. Study results presented at the 2023 European Academy of Allergy & Clinical Immunology Congress and the 2023 American College of Allergy, Asthma, and Immunology Annual Meeting demonstrated that ADP101 generated dose-dependent, clinically meaningful responses as a multi-OIT food allergy desensitization therapy, with a favorable safety and tolerability profile in pediatric patients allergic to one or more of the food sources in the product. Alladapt is also conducting the Encore Study, an open-label extension study of the Harmony study assessing long term use of ADP101 in mono- and multi-food allergic patients. Alladapt Immunotherapeutics, Inc., is a private, clinical-stage biopharmaceutical company developing prescription therapeutics targeting food allergy. In the U.S. alone, there are over 32 million people with food allergy, a prevalence similar to that of asthma or diabetes. Despite the severity and widespread presence of food allergy, the current standard of care for this serious immunologic disease is meticulous avoidance of the food allergen and emergent use of epinephrine in case of reactions caused by accidental exposure. ADP101, the Company’s lead product candidate, is an investigational oral immunotherapy representing the nine food groups responsible for the vast majority of significant food allergic reactions globally. The Company has generated positive data in the Phase 1/2 Harmony study, a randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of ADP101 for the simultaneous treatment of one or more severe food allergies in children and adults. The Encore open label extension study assessing long term use of ADP101 is ongoing, as well. Alladapt was co-founded in 2018 by biotechnology entrepreneur, Ashley Dombkowski, Ph.D., and allergist, clinician and protein biochemist, Kari Nadeau, M.D., Ph.D. Dr. Nadeau currently serves as the Chair of the Department of Environmental Health at Harvard School of Public Health and John Rock Professor of Climate and Population Studies. Food allergen specific OIT conducted by Dr. Nadeau and other food allergy experts is an approach that has shown consistent promising results through administration of increasing amounts of an allergen to individuals with food allergy to raise their reactive threshold and decrease the severity of allergic responses to the allergenic food. Allergen immunotherapy for environmental allergy and insect venom allergy is an established interventional precedent that is considered both effective and disease modifying. Oral immunotherapy for the treatment of food allergy may offer similar mechanistic promise for delivering not only desensitization but long-term disease modifying benefits. 1 Warren CM, Aktas ON, Manalo LJ, Bartell TR, Gupta RS. The epidemiology of multifood allergy in the United States: A population-based study. Ann Allergy Asthma Immunol. 2023;130(5):637-648.e5. doi:10.1016/j.anai.2022.12.031 2 U.S. Food & Drug Administration. Fast Track. Updated January 4, 2018. Accessed November 21, 2023. https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/fast-track The content above comes from the network. if any infringement, please contact us to modify.